Pictet Asset Management Holding SA Sells 34,343 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Pictet Asset Management Holding SA decreased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 526,252 shares of the specialty pharmaceutical company's stock after selling 34,343 shares during the period. Pictet Asset Management Holding SA owned 0.95% of Supernus Pharmaceuticals worth $19,029,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock worth $800,000 after acquiring an additional 560 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Supernus Pharmaceuticals by 7.3% during the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock valued at $330,000 after buying an additional 624 shares in the last quarter. Bridge City Capital LLC boosted its holdings in Supernus Pharmaceuticals by 0.8% in the 4th quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock worth $3,435,000 after buying an additional 761 shares during the period. Rhumbline Advisers raised its holdings in Supernus Pharmaceuticals by 0.5% during the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock valued at $6,236,000 after acquiring an additional 800 shares during the period. Finally, Swiss National Bank lifted its position in shares of Supernus Pharmaceuticals by 0.7% during the fourth quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock worth $3,920,000 after acquiring an additional 800 shares in the last quarter.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SUPN shares. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, April 1st.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last quarter. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN traded up $0.25 on Friday, hitting $32.74. The company's stock had a trading volume of 1,501,832 shares, compared to its average volume of 486,335. The company has a market capitalization of $1.83 billion, a PE ratio of 30.60 and a beta of 0.84. The company has a 50-day simple moving average of $34.57 and a 200 day simple moving average of $35.08. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.